HIV/AIDS HAART: Monocyte chemoattractant protein 1 mutated allele confers better response to protease inhibitors

AIDSWEEKLY Plus; Monday, September 25, 2006
Staff Medical Writers

"Antiretroviral drug efficacy has been widely studied in relation to viral factors. Mutations in the HIV coreceptors and their natural chemokines, however, may be critical in HIV infection and treatment response.

"We compared the efficacy of protease inhibitor (PI) treatment among PI-naive patients grouped according to whether they carried the chemokine CC motif receptor 2 (CCR-2) 64I and monocyte chemoattractant protein 1 (MCP-1)-2518G alleles," researchers in Spain report.

According to B. Coll and colleagues at Hospital University St. Joan in Reus, "HIV-infected patients who were PI-naive were selected for the study (n=164) but there was no restriction on lymphocyte CD4 count or plasma HIV viral load. Follow-up was for the first 24 months of treatment.

"Clinical and laboratory data were obtained every 3 months. All the participants were genotyped for the MCP-1-2518G, CCR-2 64I, CCR-5 Delta 32 and stromal derived factor 1 (SDF1) 3'A mutated alleles."

"The results indicated that patients carrying the mutated allele of MCP-1 had a higher mean CD4 cell count throughout the follow-up period than those with the common allele (p=0.01).

"Also," said the authors, "patients with the MCP-1 and CCR-2 mutated alleles were more likely to continue to have an undetectable viral load following treatment (p=0.05)."

Coll concluded, "A better response to PI treatment appears to be conferred by mutations in the host MCP-1 and CCR-2 genes, and may be related to the cellular axis-of-entry used by the retrovirus."

Coll and colleagues published their study in HIV Medicine (Influence of a monocyte chemoattractant protein 1 mutated allele on the response to protease inhibitor-based antiretroviral therapy. HIV Med. 2006 Sep;7(6):356-60).

For additional information, contact B. College, Hospital University of St. Joan, Medical Interna Service, Reus 43201, Spain.

Publisher contact information for the journal HIV Medicine is: Blackwell Publishing, 9600 Garsington Rd., Oxford OX4 2DQ, Oxon, England.

Keywords: Reus, Spain, HIV/AIDS, Monocyte Chemoattractant Protein 1 Mutated Allele, Protease Inhibitor, Response to Treatment, Viral Load.

This article was prepared by AIDS Weekly editors from staff and other reports.

Reference

Coll B, Alonso-Villaverde C, Parra S, et al., “Influence of a monocyte chemoattractant protein 1 mutated allele on the response to protease inhibitor-based antiretroviral therapy”, HIV Med. 2006 Sep;7(6):356-60.

PubMED Related articles Search

2006-09-25
AW060912

Copyright © 2006 - Charles Henderson, Publisher. All rights Reserved. Permission to reproduce granted to AEGIS by Charles W. Henderson. Authorization to reproduce for personal use granted granted by C. W. Henderson, Publisher, provided that the fee of US$4.50 per copy, per page is paid directly to the Copyright Clearance Center, 27 Congress Street, Salem, Massachusetts 01970, USA. Published by Charles Henderson, Publisher. Editorial & Publishing Office: P.O. Box 5528, Atlanta, GA 30307-0528 / Telephone: (800) 633-4931; Subscription Office: P.O. Box 830409, Birmingham, AL 35283-0409 / FAX: (205) 995-1588 http://www.newsrx.net

AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, Elton John AIDS Foundation, Bridgestone/Firestone Charitable Trust, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2006. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright © 1980,2006. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.